CMC Strategy Forum Europe 2026

Schedule

Tuesday, 23 June, 2026

06:30-07:30 Madrid Room | Level 2

The Quiet Room

The Quiet Room is a dedicated space is available throughout the forum for attendees who need a moment to recharge.

This space is intended for rest and personal wellness only - no calls, meetings, working, or noise please.

We hope you will take advantage of this resource and take care of yourselves during the week!

07:30-08:30 Foyer

Registration

Presentation type: IP - In Person

Registration will be open until 16:30.

07:30-08:30 Foyer

Coffee Service

Presentation type: IP - In Person

Start your day right with our morning Coffee and Tea Service! Coffee and tea will be served all day.

Enjoy freshly brewed coffee and tea while connecting with fellow attendees in a relaxed, welcoming atmosphere. It's the perfect opportunity to ease into the day and spark meaningful conversations!

08:30-08:45 Prague ABCD

CASSS Welcome to the 20th European CMC Strategy Forum

Presentation type: IP - In Person

Welcome and Kickoff:
Veronika Jekerle, *EMA-European Medicines Agency*
Sandra Auguste-Bowler, *Novo Nordisk A/S*

08:45-09:30 Prague ABCD

EFPIA Biomanufacturing Group Satellite Session Part I: EFPIA Biomanufacturing Updates

Karoline Bechtold-Peters, Stuart Finnie, Helen Newton
Presentation type: IP - In Person

Comparability assessment remains a central and increasingly complex element of bioconjugate development, driven by evolving manufacturing strategies, platform approaches, and expanding modality diversity. For antibody–drug conjugates (ADCs) and emerging conjugate classes, changes in process, scale, site, or control strategy raise critical questions regarding the extent of analytical, nonclinical, and clinical data required to ensure product quality and patient safety.

This session will provide a focused, regulator-engaged discussion on comparability assessment for bioconjugates, combining regulatory perspectives with practical industry experience. The program will address how established comparability principles are applied to conjugated products, where expectations align with or diverge from those for nonconjugated biologics, and which aspects of conjugate complexity most strongly influence regulatory decision-making.

Topics will include current regulatory thinking on comparability for conjugates, the role of analytical characterization and control strategies, use of prior knowledge and platform concepts, and lessons learned from real development and lifecycle management cases. Particular emphasis will be placed on practical challenges encountered in submissions, interpretation of health authority feedback, and areas where expectations remain heterogeneous or insufficiently defined.

Designed as an interactive forum, this session aims to foster dialogue between regulators and industry scientists, clarify areas of convergence and uncertainty, and support more efficient and science-based comparability strategies for current and future bioconjugate programs.

Session Speakers:

Welcome & Introduction to the EFPIA Manufacturing and Quality Expert Group (MQEG) - Biomanufacturing Satellite Session
Markus Goese, *F. Hoffmann-La Roche Ltd.*

Practical Control of Polysorbate: Degradation Is Manageable
Cyrille Chéry, *UCB Pharma SA*

Agile (Innovative) Manufacturing and Decentralized Manufacturing in Latest Regulatory Environment Including New EU Pharma Legislation
Colin Cox, *Pfizer, Inc.*

Achieving Positive Change to the Global CMC Regulatory Environment
Andrew Lennard, *Amgen Limited*

09:30-10:10 Prague ABCD

EFPIA Biomanufacturing Group Satellite Session Part II: Comparability Assessment for Bioconjugates: Regulatory Expectations, Practical Experience, and Emerging Challenges

Karoline Bechtold-Peters, Stuart Finnie, Helen Newton
Presentation type: IP - In Person

Session Speakers:

Regulatory Perspectives on Comparability Evaluation of Antibody-Drug Conjugates (ADCs)
Pavel Šimek, *State Institute for Drug Control (SÚKL)*

Comparability Strategies for Bioconjugates
Thomas Pohl, *Novartis Pharmaceuticals Manufacturing GmbH*

10:10-10:40 Foyer

Networking Break

Presentation type: IP - In Person

10:40-11:20 Prague ABCD

EFPIA Biomanufacturing Group Satellite Session Part II Continued

Karoline Bechtold-Peters, Stuart Finnie, Helen Newton
Presentation type: IP - In Person

Session Speakers:

Beyond One-Size-Fits-All: Experiences with Comparability Strategies for ADCs
Katie Duncan, *GlaxoSmithKline*

Prior Knowledge and Platform Approaches: How These Concepts Can Be Used for mAB Conjugates
Veronika Jekerle, *EMA-European Medicines Agency*

11:20-12:20 Prague ABCD

EFPIA Biomanufacturing Group Satellite Session Panel Discussion

Karoline Bechtold-Peters, Stuart Finnie, Helen Newton
Presentation type: IP - In Person

Additional Panelist:

Michelle Czajkowski, *Gilead Sciences International, Inc.*

12:20-12:25 Prague ABCD

Closing Remarks

Karoline Bechtold-Peters, Stuart Finnie, Helen Newton
Presentation type: IP - In Person

12:25-13:40 Loreta

Networking Lunch

Presentation type: IP - In Person

13:40-15:00 Prague ABCD

Session I - Regulatory Round Up: Hot Topics/Rapid Fire

Kowid Ho, Helen Newton, Mats Weilin, Florence Wolfender
Presentation type: IP - In Person

This session provides an update on the evolving global regulatory landscape by bringing together diverse perspectives from European, Swiss, and international health authorities, as well as industry experts. The session will focus on key regulatory activities occurring at local, regional, and international levels, offering insights into legislative and regulatory updates across key European and international markets. Discussion topics will include significant global and regional health initiatives, such as ICMRA collaborative efforts, recent post-approval changes guidelines, and the latest developments following the Rio ICH meeting.

Session Speakers:

Regulatory Updates: EU Insights and Global Impact
Seán Barry, *Health Products Regulatory Authority*

WHO Guidelines on Procedures and Data Requirements for Changes to Approved Vaccines and Biotherapeutics: Recent Updates
Lorenzo Tesolin, *Sciensano*

Implementation of EU Variations Guidelines - EMA Perspective
Elisa Pedone, *EMA – European Medicines Agency*

Regulatory Updates from Czechia
Barbora Ladinová, *SÚKL*

Regulatory Updates from Swissmedic
Ulla Grauschopf, *Swissmedic*

15:00-15:25 Foyer

Networking Break

Presentation type: IP - In Person

15:25-15:35 Prague ABCD

Daily Takeaway

Kowid Ho, Helen Newton, Mats Weilin, Florence Wolfender
Presentation type: IP - In Person
Session Speaker:

Richard Keane, *Biogen Idec Limited*

15:35-15:40 Prague ABCD

Introduction of Featured Speaker

Presentation type: IP - In Person
Session Speaker:

Sandra Auguste-Bowler, *Novo Nordisk A/S*

15:40-16:10 Prague ABCD

Harnessing the Power of a Multigenerational Workforce in the Biopharmaceutical Industry - Featured Speaker

Kowid Ho, Helen Newton, Mats Weilin, Florence Wolfender
Presentation type: IP - In Person
Featured Speaker

Michaela Hrdličková, *Leadership Mentor, Healthcare & Patient-Centric Care Advisor*

16:10-16:30 Prague ABCD

Featured Speaker: Q&A

Kowid Ho, Helen Newton, Mats Weilin, Florence Wolfender
Presentation type: IP - In Person

18:00-21:00 Hartigovsky Palac

Welcome Reception 20th Anniversary Event at Hartig Palace

Presentation type: IP - In Person
Join us as we celebrate the 20th Anniversary of the CMC Strategy Forum Europe at the historic Hartig Palace. Located in the charming Malá Strana quarter and adjacent to the gardens of Prague Castle, this landmark has carried many names through more than six centuries of history - from "the royal office" to "the House of the Golden Carp." Today, its beautifully restored spaces and enchanting garden provide a magnificent setting for an evening of celebration, connection, and community.

Please note: This event is open to pre-registered attendees only. Please bring your conference badge - it will be required for admission.

Getting There: Buses will depart from the hotel lobby at 5:15 PM. The event begins at 6:00 PM.

Return Bus Schedule: Return buses will depart Hartig Palace at the following times: 7:45 PM | 8:15 PM | 8:30 PM | 8:45 PM | 9:00 PM

Guests wishing to return prior to the 7:45 PM departure are welcome to make their own transportation arrangements back to the hotel.

Wednesday, 24 June, 2026

06:30-07:30 Madrid Room | Level 2

The Quiet Room

The Quiet Room is a dedicated space is available throughout the forum for attendees who need a moment to recharge.

This space is intended for rest and personal wellness only - no calls, meetings, working, or noise please.

We hope you will take advantage of this resource and take care of yourselves during the week!

07:30-08:30 Foyer

Registration

Presentation type: IP - In Person
Registration will be open until 16:00

07:30-08:30 Foyer

Coffee Service

Presentation type: IP - In Person

Start your day right with our morning Coffee and Tea Service! Coffee will be served all day.

Enjoy freshly brewed coffee and tea while connecting with fellow attendees in a relaxed, welcoming atmosphere. It's the perfect opportunity to ease into the day and spark meaningful conversations!

08:30-09:35 Prague ABCD

Session II - Next-Generation Analytics and Technology Enablers (ICH Q14)

Mihaela Buda, Joan Malmstrøm, Teresa Pepper
Presentation type: IP - In Person

As stated in the ICH Q14 guideline, an analytical procedure control strategy should ensure that the analytical procedure is fit for the intended purpose during routine use throughout its lifecycle. During the product lifecycle, modification of existing procedures or a complete replacement by introduction of a new technology can be needed to adhere to state of the art technologies. A recent example is the digital transformation, which enhances operational speed, data accessibility and predictive capabilities. Another example is the shift from N-terminal sequence analysis by Edman sequencing to the up-to-date sequence analysis by fragmentation in the mass spectrometer.

However, the implementation of new technologies presents several challenges. These may include barriers related to global implementation, lifecycle management, analytical procedure comparability, validation strategies, and regulatory acceptance across regions. This session explores challenges and opportunities, highlighting how innovation can be effectively integrated into analytical control strategies. Regulatory perspectives will be presented alongside real world industry case studies, providing practical insights into successful adoption pathways and lessons learned during the implementation of emerging analytical technologies.

Session Speakers:

New Analytical Technologies for Parenteral Drug Products
Peter Westergaard Jakobsen, *Novo Nordisk A/S*

From Data to Decision: Leveraging Advanced Analytics for Enhanced Quality Control and Regulatory Compliance
Christof Finkler, *F. Hoffmann-La Roche AG*

ICH Q14 - a Regulatory View
Martijn van der Plas, *MEB-Medicines Evaluation Board*

09:35-10:35 Loreta

Networking Break

Presentation type: IP - In Person

10:35-11:40 Prague ABCD

Session II: Panel Discussion - Q&A

Mihaela Buda, Joan Malmstrøm, Teresa Pepper
Presentation type: IP - In Person

Additional Panelist:

Thomas Pohl, *Novartis Pharma AG*

11:40-12:55 Foyer

Networking Lunch

Presentation type: IP - In Person

12:55-14:00 Prague ABCD

Session III - Predictive Stability Models (ICH Q1)

Sandra Auguste-Bowler, Karoline Bechtold-Peters, Ulla Grauschopf, Kristina Martinell
Presentation type: IP - In Person

The recent revision of the ICH Q1 guideline has opened the door for the application of enhanced stability modelling approaches and for the use of extrapolation in the development of biological products. This session will provide a comprehensive introduction to Predictive Stability Modelling, covering key modelling frameworks such as Bayesian methods and kinetic modelling approaches.

Speakers from both industry and regulatory agencies will share their perspectives on the challenges, achievements, and future expectations associated with these innovative tools. Case studies will illustrate how stability modelling can support shelf-life assignment, facilitate the assessment of post approval changes, and help reduce development timelines.

A particular focus will be placed on how predictive modelling can be integrated into science- and risk-based strategies, especially in accelerated development settings where fast and informed decision making is essential to bring medicines to patients more quickly. The session will conclude with a panel discussion offering a global outlook on current trends and regulatory convergence.

Session Speakers:

Predictive Stability Modeling: Health Canada's Risk Framework and Regulatory Readiness
Paula Russell, *Health Canada*

Stability Modelling for Biotherapeutics – a Company Perspective and Case Studies
Drago Kuzman & Salome Piuzzi, *Novartis Pharma AG*

Stability Modeling for Biologicals and Vaccines
Didier Clenet*, Sanofi*

Maintenance of ICH Stability Guideline Series - Rapid Stability Prediction Based on Modeling
Steffen Gross, *PEI – Paul-Ehrlich-Institut*

14:00-14:30 Foyer

Networking Break

Presentation type: IP - In Person

14:30-15:30 Prague ABCD

Session III: Panel Discussion - Q&A

Sandra Auguste-Bowler, Karoline Bechtold-Peters, Ulla Grauschopf, Kristina Martinell
Presentation type: IP - In Person

Additional Panelist:

Andrew Lennard, *Amgen Limited*

15:30-15:40 Prague ABCD

Daily Takeaway

Kowid Ho, Helen Newton, Mats Weilin, Florence Wolfender
Presentation type: IP - In Person

Session Speaker:

Richard Keane, *Biogen Idec Limited*

15:40-17:15 Prague ABCD

Regulators Unplugged: An Casual Conversation

Presentation type: IP - In Person

About This Session
Regulators Unplugged is a new session format introduced at CMC Strategy Forum Europe 2026, designed to foster candid, informal dialogue between regulatory authorities and the CMC community. This is not a panel - it is a conversation.

The environment is designed to be comfortable, collegial.

Please note:
The regulators joining us today are participating in their personal capacity and their comments do not represent the official positions of their respective agencies. This is an informal conversation - not every question will have a definitive answer, and that is by design. We ask that you engage in the spirit of open dialogue, and we kindly request that comments not be directly attributed or quoted externally.

Thursday, 25 June, 2026

07:00-08:00 Madrid Room | Level 2

The Quiet Room

The Quiet Room is a dedicated space is available throughout the forum for attendees who need a moment to recharge.

This space is intended for rest and personal wellness only - no calls, meetings, working, or noise please.

We hope you will take advantage of this resource and take care of yourselves during the week!

08:00-08:30 Foyer

Registration

Presentation type: IP - In Person

Registration will be open until 15:30

08:00-08:30 Foyer

Coffee Service

Presentation type: IP - In Person

Start your day right with our morning Coffee and Tea Service! Coffee will be served all day.

Enjoy freshly brewed coffee and tea while connecting with fellow attendees in a relaxed, welcoming atmosphere. It's the perfect opportunity to ease into the day and spark meaningful conversations!

08:30-08:40 Prague ABCD

Roundtable Intros and Selection (Tables 1-10)

Presentation type: IP - In Person

08:40-09:40 Prague ABCD

Roundtable Session (Tables 1 - 3)

Presentation type: IP - In Person

Table 1 - Targeted Radiopharmaceuticals – Raising Awareness of the Regulatory CMC Challenges and Approaches to Harmonising Regulatory Expectations

Table 2 - To PACMP or Not to PACMP

Table 3 - New EU Variation Classification - Experience to Date

08:40-09:40 Budapest

Roundtable Session (Tables 4 - 6)

Presentation type: IP - In Person

Table 4 - Predictive Stability Modelling - Current State and Best Practice

Table 5 - GMP Aspects

Table 6 - New EU Pharma Legislation (NPL): Analyzing the Benefits and Challenges of the New Modular Framework

08:40-09:40 Cracow

Roundtable Session (Tables 7 - 10)

Presentation type: IP - In Person

Table 7 - Sustainability and the 3Rs

Table 8 - The MDR Regulation Including the Latest Updates

Table 9 - Use of Risk-Based Approaches in CMC Filings for Biological Products

Table 10 - Expedited Approvals of Medicines for Rare Diseases

09:40-09:55 Prague ABCD

Roundtable Outcomes Wrap Up (Tables 1 - 3)

Presentation type: IP - In Person

All participants return to Ballroom at 9:55 for Roundtable Report Out

09:40-09:55 Budapest

Roundtable Outcomes Wrap Up (Tables 4 - 6)

Presentation type: IP - In Person

All participants return to Ballroom at 9:55 for Roundtable Report Out

09:40-09:55 Cracow

Roundtable Outcomes Wrap Up (Tables 7 - 10)

Presentation type: IP - In Person

All participants return to Ballroom at 9:55 for Roundtable Report Out

09:55-10:30 Prague ABCD

Roundtable Report Out (Tables 1-10)

Presentation type: IP - In Person

Each Roundtable will return to the general session room to report out for no more than 3 mins per topic.

10:30-11:35 Prague ABCD

Session IV - Modeling and AI Applications in CMC Manufacturing

Veronika Jekerle, Bridgett O'Shea, Colm Reddington, Thomas Stangler

Presentation type: IP - In Person

Advances in modeling and artificial intelligence are transforming the landscape of Chemistry, Manufacturing, and Controls (CMC), offering new opportunities to enhance product and process understanding, strengthen control strategies, and accelerate development timelines.

This session will bring together experts from regulatory authorities and industry to explore the rapidly evolving role of AI-driven and model-based approaches across the product lifecycle.

Through a series of three presentations, speakers will examine how quantitative modeling, machine learning, and emerging digital technologies are being applied in real-world manufacturing and process development.

Case studies will illustrate the use of mechanistic models, data-driven tools, and digital twins to support process design, optimization, and robustness, highlighting both successes and lessons learned. In parallel, regulators will share insights into current expectations and considerations for the use of modeling and AI within CMC submissions, including topics such as data integrity, model validation, transparency, and lifecycle management.

The session will conclude with a panel discussion to explore practical challenges and future directions, including how industry and regulators can collaboratively shape clear, science-based pathways for the adoption of AI in CMC.

Attendees will gain a deeper understanding of best practices, regulatory perspectives, and implementation strategies to advance model-enabled and AI-augmented approaches within their own organizations

Session Speakers:

The EU Quality Innovation Group Perspective on Modelling and AI in Pharmaceutical Process Development and Manufacturing
Leticia Martinez-Peyrat, *French National Agency for Medicines and Health Products Safety*

AI Powered End-to-End Process Digital Twins: Applications, Benefits and Challenges
Thomas Zahel, *Koerber Pharma Austria GmbH*

Digital CMC Transformation Driven by Modelling and Agentic AI
Mónica Perea-Vélez, *GlaxoSmithKline*

11:35-12:35 Loreta

Networking Lunch

Presentation type: IP - In Person

12:35-13:35 Prague ABCD

Session IV: Panel Discussion - Q&A

Veronika Jekerle, Bridgett O'Shea, Colm Reddington, Thomas Stangler
Presentation type: IP - In Person

Additional Panelist:
Mie Bach-Pedersen, *Novo Nordisk A/S*

13:35-14:00 Foyer

Stretch Break

Presentation type: IP - In Person

14:00-15:25 Prague ABCD

Session V - Evolution of Endotoxin Testing

Katrin Buss, Lionel Randon, Martijn van der Plas
Presentation type: IP - In Person

Endotoxin testing is at the cornerstone of the control strategy for Parenteral medicinal products, historically dependent on the standard and compendial Limulus Amoebocyte Lysate (LAL) assay.

In alignment with the 3R EU Commission's vision, the pharmaceutical industry is prioritizing sustainability, operational efficiency, and a reduction in the use of animal-derived reagents. To meet these goals, innovative alternatives to Limulus Amoebocyte Lysate (LAL) are being explored ensuring that the robustness and reliability required for pharmaceutical applications are maintained.

Among these alternatives, monocyte activation testing (MAT), recombinant Factor C (rFC) methods and the recombinant Chromogenic Reagent (rCR) stands out as current or future promising methods to address these challenges.

This conference session aims to leverage collaborative exchanges and shared knowledge to establish viable alternatives to LAL.

By bringing together industry expertise, best practices, and regulatory perspectives, the session intend is to provide actionable guidance for developing, validating, and adopting LAL alternatives in regulatory and scientific contexts.

Key Focus Areas will be:

Sustainability: Reducing environmental impact by transitioning away from animal-derived reagents.

Scientific Validation: Ensuring LAL alternative method meets the rigorous standards required for pharmaceutical applications (while also addressing the opportunity to mitigate the LER effect).

Industry Case Studies: Highlighting real-world examples and lessons learned from companies.

Transition Strategies: Supporting the ongoing use of recombinant and LAL tests as alternatives during an interim phase, avoiding unnecessary comparative evidence and enabling a smooth transition.

Session Speakers:

From LAL to Recombinant Methods - Regulatory Expectations and Challenges in the EU
Barbora Ladinová, *SÚKL*

Evolution of Pyrogen and Endotoxin Testing in Plasma derived Medicinal Products (PDMPs) and Vaccines
René Gysin, *Swissmedic*

Regulatory Challenges of Recent Low Endotoxin Recovery Queries
Jody Peraino, Pfizer, Inc.

Regulatory Strategy to Enable Enterprise-Wide Replacement of LAL With Recombinant Cascade Reagent (rCR) Technology
Amanda Jacobs, *AstraZeneca*

15:25-15:45 Foyer

Networking and Coffee Break

Presentation type: IP - In Person

15:45-16:45 Prague ABCD

Session V: Panel Discussion - Q&A

Katrin Buss, Lionel Randon, Martijn van der Plas
Presentation type: IP - In Person
Additional Panelists:

Ingo Spreitzer, *Paul-Ehrlich-Institut*
Emmanuelle Coppens, *Sanofi*

16:45-17:00 Prague ABCD

Closing Remarks & Invitation to the CMC Strategy Forum 2027

Presentation type: IP - In Person

Friday, 26 June, 2026

08:00-08:30 9th Floor

Registration for Short Course Attendees Only

Presentation type: IP - In Person

08:00-08:30 Loft 1 (9th Floor)

Short Course Information

Presentation type: IP - In Person

You do not need to be registered for the Forum to participate in the Short Course. We highly encourage attendees to participate in both the Forum and Short Course to maximize their CMC learning experience. Registration for the short course is not included in the Forum registration fee. The Short Course requires an additional registration, which can be added to your Forum registration at the time of purchase.

The morning session on "From Regulatory Framework to Development Realities: ADCs and AOCs" establishes the regulatory landscape for conjugates and traces the development journey from early- to late-stage through real-world case studies, including a direct comparison of ADCs and AOCs and strategies for accelerating development timelines. The afternoon session on "Advanced Strategies: Platforms, Emerging Technologies, and the Road Ahead" explores advanced topics including platform concepts and DMF opportunities, imaging with radioconjugates and China-specific regulatory considerations, and the use of modelling and AI to derisk toxicology, stability, and overall developability, culminating in a one-hour moderated panel discussion. We encourage all professionals, from early-career to senior-level, to participate in this opportunity.

This short course on conjugates, held in conjunction with the CASSS EU CMC Strategy Forum in Prague, provides a comprehensive and crossfunctional exploration of current and emerging considerations in the development of conjugate modalities. Spanning scientific, technical, and regulatory dimensions, the program brings together expert speakers and incorporates structured discussion to facilitate deep engagement and knowledge exchange.

The course opens with a regulatory overview, followed by case studies illustrating both earlystage and latestage development challenges for ADCs and AOCs. Sessions address core differentiators between conjugate classes, accelerated development scenarios, and opportunities arising from platform concepts and platform DMFs. Further topics include imaging applications with radioconjugates—highlighting regionspecific requirements such as those relevant to China—and forwardlooking approaches using modelling and AI for derisking toxicology, stability, and overall developability. The program concludes with a dedicated onehour panel discussion to synthesize insights across scientific and regulatory perspectives.

Designed to be accessible for newcomers while offering substantial depth for experienced practitioners, the course aims to equip participants with both foundational understanding and advanced, modalityspecific expertise in the rapidly evolving conjugates landscape.

08:30-09:00 Loft 1 (9th Floor)

Welcome and Course Introduction

Karoline Bechtold-Peters, Katie Duncan, Kanny Wan
Presentation type: IP - In Person

09:00-10:00 Loft 1 (9th Floor)

Short Course AM - Part 1 - From Regulatory Framework to Development Realities: ADCs and AOCs

Karoline Bechtold-Peters, Katie Duncan, Kanny Wan
Presentation type: IP - In Person

This session establishes the regulatory landscape for conjugates and traces the development journey from early- to late-stage through real-world case studies, including a direct comparison of ADCs and AOCs and strategies for accelerating development timelines.

Short Course Topics:

Development of Antibody Conjugates as Specific and Potent Medicinal Products - a Regulator´s Perspective
Steffen Gross, *PEI – Paul-Ehrlich-Institut*

From Change to Approval Faster: Accelerating ADC Manufacturing Changes via PACMP, ICMRA and WHO Reliance
Michelle Czajkowski, *Gilead Sciences International, Ltd.*

10:00-10:30 Loft 1 (9th Floor)

Refreshment Break

Presentation type: IP - In Person

10:30-11:30 Loft 1 (9th Floor)

Short Course AM - Part 2 - Continued

Karoline Bechtold-Peters, Katie Duncan, Kanny Wan
Presentation type: IP - In Person

Short Course Topics:

Global Regulatory Frameworks for Conjugates: From EFPIA Smart Approaches to Regional Implementation
Katie Duncan, *GlaxoSmithKline*

Case Study on Commercial ADC
David Koziel, *Daiichi Sankyo Europe GmbH*

11:30-12:30 Loft 1 (9th Floor)

Short Course AM - Panel Discussion - Regulatory Challenges of Bioconjugates

Presentation type: IP - In Person

12:30-13:45 Loft 1 (9th Floor)

Lunch Break

Presentation type: IP - In Person

13:45-15:15 Loft 1 (9th Floor)

Short Course PM - Advanced Strategies: Platforms, Emerging Technologies, and the Road Ahead

Presentation type: IP - In Person

This session explores advanced topics including platform concepts and DMF opportunities, imaging with radioconjugates and China-specific regulatory considerations, and the use of modelling and AI to derisk toxicology, stability, and overall developability, culminating in a one-hour moderated panel discussion.

Short Course Topics:

Differences and Similarities Between ADCs and AOCs
Manjappa Lingaraju Gondichatnahalli, *Novartis Pharma AG*

Antibody Oligonucleotide Conjugates: Development, Delivery, and Challenges
Rachel Johns, *Avidity Biosciences, Inc.*

Imaging Using Radioconjugates: Overview, Global Quality Guidance and Regulatory Pathways
Hayley Jackman, *AstraZeneca*

15:15-15:30 Loft 1 (9th Floor)

Coffee Break

Presentation type: IP - In Person

15:30-16:30 Loft 1 (9th Floor)

Short Course PM - Panel Discussion - Practice of Conjugates

Presentation type: IP - In Person